DBCCF
Price
$0.08
Change
-$0.00 (-0.00%)
Updated
Jan 14 closing price
Capitalization
41.54M
Intraday BUY SELL Signals
ESALF
Price
$30.61
Change
+$0.61 (+2.03%)
Updated
Jan 14 closing price
Capitalization
8.29B
Intraday BUY SELL Signals
Interact to see
Advertisement

DBCCF vs ESALF

Header iconDBCCF vs ESALF Comparison
Open Charts DBCCF vs ESALFBanner chart's image
Decibel Cannabis
Price$0.08
Change-$0.00 (-0.00%)
Volume$2.96K
Capitalization41.54M
Eisai
Price$30.61
Change+$0.61 (+2.03%)
Volume$130
Capitalization8.29B
DBCCF vs ESALF Comparison Chart in %
DBCCF
Daily Signal:
Gain/Loss:
ESALF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DBCCF vs. ESALF commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DBCCF is a Hold and ESALF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (DBCCF: $0.08 vs. ESALF: $30.61)
Brand notoriety: DBCCF and ESALF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DBCCF: 2% vs. ESALF: 33%
Market capitalization -- DBCCF: $41.54M vs. ESALF: $8.19B
DBCCF [@Pharmaceuticals: Generic] is valued at $41.54M. ESALF’s [@Pharmaceuticals: Generic] market capitalization is $8.19B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DBCCF’s FA Score shows that 1 FA rating(s) are green whileESALF’s FA Score has 2 green FA rating(s).

  • DBCCF’s FA Score: 1 green, 4 red.
  • ESALF’s FA Score: 2 green, 3 red.
According to our system of comparison, DBCCF is a better buy in the long-term than ESALF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DBCCF’s TA Score shows that 4 TA indicator(s) are bullish while ESALF’s TA Score has 5 bullish TA indicator(s).

  • DBCCF’s TA Score: 4 bullish, 4 bearish.
  • ESALF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both DBCCF and ESALF are a good buy in the short-term.

Price Growth

DBCCF (@Pharmaceuticals: Generic) experienced а +2.82% price change this week, while ESALF (@Pharmaceuticals: Generic) price change was -4.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.08%. For the same industry, the average monthly price growth was +6.77%, and the average quarterly price growth was +19.08%.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESALF($8.3B) has a higher market cap than DBCCF($41.5M). ESALF has higher P/E ratio than DBCCF: ESALF (27.85) vs DBCCF (3.52). ESALF YTD gains are higher at: 2.977 vs. DBCCF (-3.144). ESALF has higher annual earnings (EBITDA): 110B vs. DBCCF (20.7M). ESALF has more cash in the bank: 302B vs. DBCCF (6.08M). DBCCF has less debt than ESALF: DBCCF (45.8M) vs ESALF (237B). ESALF has higher revenues than DBCCF: ESALF (804B) vs DBCCF (109M).
DBCCFESALFDBCCF / ESALF
Capitalization41.5M8.3B1%
EBITDA20.7M110B0%
Gain YTD-3.1442.977-106%
P/E Ratio3.5227.8513%
Revenue109M804B0%
Total Cash6.08M302B0%
Total Debt45.8M237B0%
FUNDAMENTALS RATINGS
DBCCF vs ESALF: Fundamental Ratings
DBCCF
ESALF
OUTLOOK RATING
1..100
5689
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
8
Undervalued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
427
PRICE GROWTH RATING
1..100
5852
P/E GROWTH RATING
1..100
1565
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESALF's Valuation (8) in the null industry is somewhat better than the same rating for DBCCF (49). This means that ESALF’s stock grew somewhat faster than DBCCF’s over the last 12 months.

DBCCF's Profit vs Risk Rating (89) in the null industry is in the same range as ESALF (100). This means that DBCCF’s stock grew similarly to ESALF’s over the last 12 months.

ESALF's SMR Rating (7) in the null industry is somewhat better than the same rating for DBCCF (42). This means that ESALF’s stock grew somewhat faster than DBCCF’s over the last 12 months.

ESALF's Price Growth Rating (52) in the null industry is in the same range as DBCCF (58). This means that ESALF’s stock grew similarly to DBCCF’s over the last 12 months.

DBCCF's P/E Growth Rating (15) in the null industry is somewhat better than the same rating for ESALF (65). This means that DBCCF’s stock grew somewhat faster than ESALF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DBCCFESALF
RSI
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 2 days ago
54%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
64%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
50%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
40%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
51%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 3 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
67%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
DBCCF
Daily Signal:
Gain/Loss:
ESALF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FREL27.630.25
+0.91%
Fidelity MSCI Real Estate ETF
IFLO29.380.19
+0.64%
VictoryShares Intl Free Csh Flow ETF
UEVM58.520.34
+0.59%
VictoryShares Emerging Mkts Val MomtETF
MARO8.490.05
+0.59%
Yieldmax Mara Option Income Strategy ETF
MNBD26.15N/A
N/A
ALPS Intermediate Municipal Bond ETF

ESALF and

Correlation & Price change

A.I.dvisor tells us that ESALF and ESAIY have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESALF and ESAIY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESALF
1D Price
Change %
ESALF100%
+2.03%
ESAIY - ESALF
26%
Poorly correlated
-0.54%
DVAX - ESALF
23%
Poorly correlated
-0.76%
KHTRF - ESALF
22%
Poorly correlated
+0.23%
SHPH - ESALF
22%
Poorly correlated
+6.29%
BLMH - ESALF
21%
Poorly correlated
-3.33%
More